Navigation Links
Metabolic Solutions Development Company Launches Phase 2a Trial of Its Second Compound to Treat Type 2 Diabetes
Date:3/29/2011

KALAMAZOO, Mich., March 29, 2011 /PRNewswire/ -- Metabolic Solutions Development Company (MSDC), a drug discovery and development company exploiting novel molecular targets to treat metabolic diseases, announced today that it has launched a Phase 2a trial for MSDC-0602, the company's second drug candidate for the treatment of type 2 diabetes.  The 28-day, randomized, double-blind, comparator- and placebo-controlled clinical trial will involve approximately 125 patients at 15 planned sites throughout the United States.

MSDC-0602 is a selective modulator of mitochondrial metabolism that modifies nutrient-sensing pathways leading to improved insulin action without direct activation of nuclear transcription factors.  "Because this novel mechanism of action does not depend on direct activation of nuclear transcription factors, type 2 diabetic patients treated with MSDC-0602 are not expected to experience fluid retention or weight gain as do patients treated with the currently marketed PPARy agonists," said Dr. Jerry Colca, president and chief scientific officer of MSDC.  

In addition to gathering additional safety and tolerability data, the Phase 2a trial will evaluate the reduction in fasting plasma glucose following once-daily dosing for 28 consecutive days in patients with type 2 diabetes.  Patients taking MSDC-0602 will be compared to those taking 45 mg of pioglitazone and placebo. This study follows the completion of two Phase 1 trials.  No safety concerns were observed in those studies. Following this Phase 2a trial, additional safety and expanded efficacy data will be gathered in a Phase 2b study of MSDC-0602 that is targeted to begin in the first quarter of 2012.

In October 2010, MSDC announced that it had raised $23.5 million to conduct the Phase 2a trial of MSDC-0602 and complete the Phase 2b study of MSDC-0160, the company's pioneer compound for the treatment of metabolic diseases associated with altered mitochondrial function.

Diabetes is marked by high levels of blood glucose resulting from defects in insulin production, insulin action, or both.  According to the American Diabetes Association and Centers for Disease Control, more than 23 million Americans have type 2 diabetes and another 70 million have been identified as having pre-diabetes (i.e., having blood glucose or HbA1c levels higher than normal but not high enough to be classified as diabetes). Diabetes can lead to serious complications and premature death. Complications include heart disease and stroke, hypertension, blindness and eye problems, kidney disease, diseases of the nervous system, dental diseases, and amputations. The annual total cost of diabetes in the United States is approximately $174 billion.

About Metabolic Solutions Development Company (MSDC)

Metabolic Solutions Development Company (www.msdrx.com) is a drug discovery and development company exploiting novel molecular targets to develop new therapies for metabolic diseases associated with altered mitochondrial function, especially insulin resistance and type 2 diabetes.  The company has raised nearly $50 million in support of the development of its pioneer and lead products, MSDC-0160 (currently in Phase 2b) and MSDC-0602 (currently in Phase 2a), which are new insulin sensitizers that have been shown to be effective in reducing fasting plasma glucose without the unwanted side effects associated with direct activation of nuclear transcription factors.  Founded in 2006 by former Pfizer researchers Jerry Colca, Ph.D. and Rolf Kletzien, Ph.D., MSDC is headquartered in Kalamazoo, Michigan.

CONTACT:
Nick Wasmiller
SeyferthPR
1-800-435-9539
wasmiller@seyferthpr.com


'/>"/>
SOURCE Metabolic Solutions Development Company
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Dave Anderson and William Thomsen Join SRI Internationals Center for Advanced Drug Research to Lead Programs in Proteomics and Metabolic Disease Drug Discovery
2. Bionovo Announces Publication Describing How Metabolic Adaptability Contributes to the Metastasis of Tumors
3. Metabolic Status Before Pregnancy Predicts Subsequent Gestational Diabetes
4. Metabolic Solutions Development Company to Present Research Findings to European Association for the Study of Diabetes
5. Windhover Information Names D-Tagatose One of Top 10 Most Promising CV/Metabolic Drugs in Development
6. Isis Highlights New Data on Antisense Drugs to Treat Type 2 Diabetes and Obesity From Its Broad Metabolic Disease Franchise at ADA Scientific Sessions
7. Reportlinker Adds Stakeholder Opinions: Cardiovascular and Metabolic Generics - Generics continue to gain prominence
8. Isis Pharmaceuticals to Discuss Its Metabolic Franchise in a Conference Call on Wednesday, April 28
9. Reportlinker Adds Metabolic Endocrinology Hypocalcemia
10. Metabolic Solutions Development Company To Test Potential Treatment for Alzheimers
11. Cardax Pharmaceuticals Nominates Clinical Candidate Heptax for Liver Disease; Heptax Ameliorates Inflammation and Oxidative Stress Related to Liver Disease and Metabolic Syndrome
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/30/2017)... , June 30, 2017 In vitro ... the start of May, at least ten diagnostic companies ... private investments, public offerings and a loan facility.  The ... to almost $80 million.  Kalorama Information provides a monthly ... its Diagnostics Knowledge Center. ...
(Date:6/30/2017)... HIGH POINT, N.C. , June 29, 2017  Axium Pharmaceuticals ... innovations for developing improved novel formulations and alternative dosage forms ... ... transmucosal delivery is based on our waterless self-nano emulsifying formula, ... after contact with saliva. We believe the spray will provide ...
(Date:6/27/2017)... , Jun 27, 2017   NuEyes (NuEyes Technologies ... funding to fuel its growth in helping the legally blind ... (Osterhout Design Group), the leading developer of augmented, virtual and ... sits. The undisclosed funding amount was provided by ... Arab Angel, with offices in Abu Dhabi ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... West Dermatology is pleased to announce the ... July 17, 2017, Ms. Vu will join West Dermatology’s large network of medical and ... skin cancer , and more. She graduated from the University of Florida College ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... (ACL) offer patients improved quality of life five years after injury, according to ... Annual Meeting in Toronto, Ontario, Canada. The study followed patients for five years ...
(Date:7/20/2017)... Viejo, CA (PRWEB) , ... July 20, 2017 , ... ... when placed between two clips in the FCPX timeline. This effect isolates horizontal and ... transition in this package contains either a rotating or flipping animation and can be ...
(Date:7/20/2017)... ... July 20, 2017 , ... Acute myeloid leukemia (AML) ... progresses rapidly without treatment. Newly diagnosed patients face intense chemotherapy regimens and a ... relapse. With such a challenging diagnosis that requires immediate action, patients and ...
(Date:7/20/2017)... (PRWEB) , ... July 20, 2017 , ... ... law firm headquartered in Houston, is pleased to announce their expansion to the ... affordable housing experience, directors Alysse Hollis and Ronald Bell, and of counsels, John ...
Breaking Medicine News(10 mins):